Citius Oncology, Inc. (CTOR) dividends
CTOR on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Citius Oncology, Inc. dividend: key facts
Own Citius Oncology, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next CTOR dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London11 Nov 2026 · PRNewsWire
Chairman and CEO Leonard Mazur to host one-on-one business development meetings CRANFORD, N.J., Nov. 11, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: C...
- Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe4 Nov 2026 · PRNewsWire
Data featured in oral presentation at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) 2026 Annual Meeting in Berlin Patients who responded t...
- Citius reports 120% growth in shipments of LYMPHIR units to U.S. wholesalers26 Oct 2026 · TheFly
Citius Oncology (CTOR)announced preliminary, unaudited LYMPHIR unit sales to U.S. wholesalers and institutional vial orders for the fiscal fourth quarter ended September 30, 2026. Preliminary Fiscal F...
- Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 202626 Oct 2026 · PRNewsWire
CRANFORD, N.J., Oct. 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of ...
- Citius Pharmaceuticals to Participate in October 2026 Investor Conferences17 Oct 2026 · PRNewsWire
Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the 2026 Maxim Growth Summit and the ThinkEquity Conference CRANFORD, N.J., Oct. 12, 2026 /PRNewswire/ -- Citius Phar...
- Citius Pharmaceuticals to Participate in September 2026 Investor Conferences15 Sep 2026 · PRNewsWire
Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth & Lif...
- Citius Oncology reports availability of Lymphir in institutions grew 78% in Q316 Aug 2026 · TheFly
Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, (CTXR), provided an update on the expanding base of institutions ordering LYMPHIR, or denileukin diftitox-cxdl through wh...
- Citius Oncology provides update on commercial launch of Lymphir16 Aug 2026 · TheFly
Citius Oncology (CTOR), majority-owned subsidiary of Citius Pharmaceuticals (CTXR), provided an update on the commercial launch of Lymphir â denileukin diftitox-cxdl -. Citius Oncology has expanded it...
Insufficient verified data for a financial-health score
Dividend data and price last updated 17 Nov 2026.